Comparative Pharmacology
Head-to-head clinical analysis: AMANTADINE versus XERESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMANTADINE versus XERESE.
AMANTADINE vs XERESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.
XERESE is a fixed-dose combination of clobetasol propionate (a corticosteroid) and acitretin (a retinoid). Clobetasol propionate binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines and reduce inflammation. Acitretin binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), regulating keratinocyte proliferation and differentiation.
100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).
One vaginal tablet (100 mg clindamycin + 200 mg clotrimazole) intravaginally once daily at bedtime for 3 consecutive days.
None Documented
None Documented
Clinical Note
moderateAmantadine + Haloperidol
"The therapeutic efficacy of Haloperidol can be decreased when used in combination with Amantadine."
Clinical Note
moderateAmantadine + Mifepristone
"Amantadine may increase the QTc-prolonging activities of Mifepristone."
Clinical Note
moderateAmantadine + Promazine
"The therapeutic efficacy of Promazine can be decreased when used in combination with Amantadine."
Clinical Note
moderateAmantadine + Chlorpromazine
Terminal elimination half-life: 10-14 hours in young adults, up to 24 hours in elderly; prolonged to >24 hours in renal impairment
Terminal half-life is approximately 8.5 hours (6–11 h) in healthy adults, supporting twice-daily dosing.
Renal: 90% as unchanged drug via glomerular filtration and tubular secretion; fecal: <10%
Renal: ~51% as unchanged drug; fecal: ~33% (partially as metabolites).
Category C
Category C
Antiviral / Antiparkinsonian
Antiviral
"The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Amantadine."